N/A N=53 Effects of S. Boulardii and Amoxicillin/Clavulanate on Gut Microbiota
Healthy Volunteers
Primary: Gastrointestinal Symptom Rating Scale — 18.7; 18.7; 17.3 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=503 Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris
Acne Vulgaris
Primary: Success Rate — 33.7; 27.3; 11.0; 31.9 percentage of participants
Phase 4 N=20 Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS
Transplantation · Immunosuppression · Drug Interaction
Primary: Dose-normalized AUC of Mycophenolic Acid — 41; 38; 43; 46 mg*h/L
N/A N=449 Residual Gastric Volume in Same Day Versus Split Dose and Evening Before Bowel Preparation
Esophagogastroduodenoscopy · Colonoscopy
Primary: Residual Gastric Volumes of Different Bowel Preparation Regimens — 19; 16; 18 mL
Phase 2 N=59 Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)
Refractory Leukemia · Acute Myelogenous Leukemia
Primary: Best Response as Per Investigator Assessment by Stratum (FAS) — 3.1; 7.4; 0; 3.7 Percentage of Participants
N/A N=23 Secretin-Stimulated Magnetic Resonance Cholangiopancreatography (S-MRCP) in Pancreatic Patients
Pancreatic Cancer
Primary: S-MRCP and S-EUS Concordance
Phase 4 N=97 Patient Education in Adherence on Acne (PEAce)
Acne
Primary: Mean Rate of Adherence, as Assessed by Medical Event Monitoring System (MEMS) — 63.1; 56.5; 48.2 percentage of adherence — p=0.3165
Phase 3 N=353 HeartLight Ablation in Patients With Paroxysmal Atrial Fibrillation (PAF)
Paroxysmal Atrial Fibrillation
Primary: Number of Participants That Meeting the Efficacy Success Criteria as Described in the Outcome Measure Description — 102; 103 Successful Participants
Phase 3 N=120 SONOlysis in Risk REduction of Symptomatic and Silent Brain infarCtions dUring Cardiac surgEry
Coronary Artery Bypass Graft Redo · Heart Valve Diseases
Primary: Number od Participants With New Brain Infarction in the Monitored MCA Territory Detected Using MRI — 8; 16; 52; 44 participants — p=<0.05
Phase 1 N=41 A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer, · Primary Peritoneal Cancer or Endometrial Cancer · Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer
Primary: Dose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Paclitaxel Combination Via Reporting of Dose-limiting Toxicity (DLT) — 0…
Phase 3 N=242 SONOlysis in Prevention of Brain Infarctions dUring Carotid Stenting and caroTid EndaRterectomy
Internal Carotid Artery Stenosis
Primary: Participants With a New Brain Infarction Detected Using Magnetic Resonance — 5; 15; 33; 42 participants
Phase 1 N=48 A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
Colorectal Cancer · Squamous Cell Head and Neck Cancer · Non-small Cell Lung Cancer
Primary: Dose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Cetuximab and the MM-121 Plus Cetuximab Plus Irinotecan Combination — 1…
Phase 2 N=51 A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
Neoplasms
Primary: Best Overall Response Rate in TKI-Naive Participants — 42.3 percentage of participants
N/A N=622 Creating a Clinic-Community Liaison Role in Primary Care: Engaging Patients and Community in Health Care Innovation
Patient Engagement · Community Integration
Primary: Number of Participants Receiving a Resource for Community Services — 356 participants
Phase 3 N=138 Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)
Hemophilia A
Primary: Annualized Bleeding Rate (ABR) — 4.3; 43.4 Bleeds per year — p=<0.0001